{"id":"sofosbuvir-ledipasvir-x-12-weeks","safety":{"commonSideEffects":[{"rate":"14-19%","effect":"Headache"},{"rate":"11-14%","effect":"Fatigue"},{"rate":"8-10%","effect":"Nausea"},{"rate":"5-8%","effect":"Diarrhea"},{"rate":"4-6%","effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL2374220","moleculeType":"Small molecule","molecularWeight":"889.02"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sofosbuvir is a nucleotide analog that acts as a chain terminator of the HCV RNA-dependent RNA polymerase (NS5B), preventing viral RNA synthesis. Ledipasvir is a non-structural protein 5A (NS5A) inhibitor that disrupts viral replication and assembly. Together, this fixed-dose combination provides direct-acting antiviral activity against hepatitis C virus across multiple genotypes.","oneSentence":"Sofosbuvir inhibits hepatitis C virus NS5B polymerase while ledipasvir inhibits NS5A protein, together blocking viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:38.371Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, genotypes 1, 4, 5, and 6"},{"name":"HCV in patients with compensated cirrhosis"}]},"trialDetails":[{"nctId":"NCT02759861","phase":"PHASE4","title":"Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2016-08-01","conditions":"Genotype 1 Hepatitis C Virus","enrollment":16},{"nctId":"NCT02249182","phase":"PHASE2","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-11-05","conditions":"Hepatitis C Virus Infection","enrollment":226},{"nctId":"NCT02868242","phase":"PHASE2","title":"Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-08-28","conditions":"Hepatitis C Virus Infection","enrollment":19},{"nctId":"NCT02347345","phase":"PHASE4","title":"Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2016-11-15","conditions":"Hepatitis C","enrollment":34},{"nctId":"NCT02631772","phase":"PHASE4","title":"LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2016-06-01","conditions":"Hepatitis C","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Harvoni"],"phase":"marketed","status":"active","brandName":"Sofosbuvir/Ledipasvir x 12 weeks","genericName":"Sofosbuvir/Ledipasvir x 12 weeks","companyName":"Medical University of South Carolina","companyId":"medical-university-of-south-carolina","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sofosbuvir inhibits hepatitis C virus NS5B polymerase while ledipasvir inhibits NS5A protein, together blocking viral replication. Used for Chronic hepatitis C virus (HCV) infection, genotypes 1, 4, 5, and 6, HCV in patients with compensated cirrhosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}